Latest News
18
May2022
LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate virtually ... Read More
May 18, 2022John Copertino
12
May2022
FYARRO net product sales of $2.3 million in partial first quarter
Dosing of patients initiated in PRECISION 1, a Phase 2 tumor-agnostic registration-directed trial evaluating nab-sirolimus in TSC1 or TSC2 altered solid tumors
Conference call to be held today at 8:30 am EDT
LOS ANGELES, May 12, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical ... Read More
May 12, 2022John Copertino
09
May2022
Company enters into collaborations with leading next generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial
Collaborations will expedite identification of advanced cancer patients with Tuberous Sclerosis Complex 1 and 2 (“TSC1” and “TSC2”) inactivating alterations, a population with a projected US incidence ... Read More
May 9, 2022John Copertino
04
May2022
LOS ANGELES, May 04, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today reported it has received notification of a product-specific, permanent J-code for FYARROTM (sirolimus protein-bound particles for injectable ... Read More
May 4, 2022John Copertino
28
Apr2022
LOS ANGELES, April 28, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will report results for the first quarter 2022 before market open on Thursday, May ... Read More
April 28, 2022John Copertino
18
Apr2022
LOS ANGELES, April 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi's ... Read More
April 18, 2022John Copertino
01
Mar2022
LOS ANGELES, March 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq:AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will participate in a panel discussion on Tumor-Agnostic Development and ... Read More
March 1, 2022John Copertino
23
Feb2022
FYARRO™ added to NCCN® Guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
PRECISION-1 tumor agnostic study for TSC1 or TSC2 alterations
is open for enrollment –
LOS ANGELES, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focusing on precision therapies for ... Read More
February 23, 2022John Copertino
23
Nov2021
FYARRO is the first and only approved therapy for adults for the treatment of malignant PEComa, an ultra-rare and aggressive form of sarcoma with a strong female predominance
FYARRO launch planned for Q1 2022; Investor call to be held today at 8:30 am ET
LOS ANGELES, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) ... Read More
November 23, 2021John Copertino